Alfredo
Carrato Mena
Profesor/a Emérito/a
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (19)
2021
-
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
Genome Medicine, Vol. 13, Núm. 1
-
Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses
Gut, Vol. 70, Núm. 2, pp. 319-329
-
Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), Vol. 30, Núm. 6, pp. 423-430
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain
Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26
2020
-
Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 29, Núm. 5, pp. 1009-1018
-
Treatment patterns for metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462
2019
-
Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case–control approaches
International Journal of Cancer, Vol. 144, Núm. 7, pp. 1540-1549
-
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials
ESMO Open, Vol. 4, Núm. 6
2018
-
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients
Targeted Oncology, Vol. 13, Núm. 1, pp. 69-78
-
Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients (Targeted Oncology, (2018), 13, 1, (69-78), 10.1007/s11523-017-0536-z)
Targeted Oncology
-
Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives
International Journal of Epidemiology, Vol. 47, Núm. 2, pp. 473-483
2017
-
A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1618-1624
-
Reduced risk of pancreatic cancer associated with asthma and nasal allergies
Gut, Vol. 66, Núm. 2, pp. 314-322
2016
-
Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of european ancestry
Human Molecular Genetics, Vol. 25, Núm. 6, pp. 1203-1214
2015
-
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: Results of the PANCOSTABRAX study
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 4, pp. 579-589
2014
-
Genome-wide association study identifies multiple loci associated with bladder cancer risk
Human Molecular Genetics, Vol. 23, Núm. 5
-
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633
-
The 19q12 bladder cancer GWAS signal: Association with cyclin E function and aggressive disease
Cancer Research, Vol. 74, Núm. 20, pp. 5808-5818